Patient Financial Assistance
Genentech Rheumatology Access Solutions—connecting your patients to their medicine. We are committed to helping all patients access our medicines, regardless of their ability to pay.
ACTEMRA Copay Card Program
Genentech Rheumatology Access Solutions offers the ACTEMRA Copay Card to help qualified patients with the out-of-pocket (OOP) costs associated with their ACTEMRA prescription.
The ACTEMRA Copay Card Program provides a prepaid debit card with up to $4000 in co-pay assistance per 12-month period. The card can be used once per month for your patients' co-pays.
To enroll and learn complete program details and eligibility requirements, call 1-888-MY-ACTEMRA (1-888-692-2836) or visit ACTEMRAcard.com
In the next section, you'll find additional information and services that can help simplify the coverage and reimbursement process for you and your patients.
INDICATION
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders, malignancies, and changes to certain lab parameters.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
